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The anti-metabolite thiopurine medications, azathioprine (AZA, 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine) and 6-mercaptopurine (6-MP), are important therapies for both induction and maintenance of remission in patients with Crohn's disease and ulcerative colitis (Pearson et al., 1995; Egan and Sandborn, 2004) . Although originally developed for use in leukemia, AZA and 6-MP are now commonly used for their immunosuppressive properties in solid organ transplantation, autoimmune hepatitis, rheumatoid arthritis and autoimmune dermatologic diseases in addition to inflammatory bowel disease (Lake et al., 2000) . Once ingested, these drugs enter a metabolic pathway that is complex and produces several different final products. AZA is non-enzymatically converted to 6-MP, which can be metabolized to the inactive metabolites 6-thiouric acid via xanthine oxidase, or 6-methylmercaptopurine via thiopurine methyltransferase. 6-Thioguanine nucleotides (6-TGN), which are active metabolites of AZA and 6-MP, are produced through the sequential actions of hypoxanthine phosphoribosyl transferase, inosine monophosphate dehydrogenase and guanosine monophosphate synthetase (Aarbakke et al., 1997) . In lymphocytes, this results in the depletion of purine nucleotides, especially those containing adenosine (Dayton et al., 1992) . As a consequence of the lack of purine nucleotides, 6-TGN inhibit the synthesis and utilization of precursors of DNA, effects which probably underlie the anti-proliferative actions of AZA and 6-MP. However, in addition to the formation of precursors of DNA, purine nucleotides are also essential in RNA synthesis, and in phosphorylation and glycosylation reactions. This complexity raises the possibility that thiopurine drugs might have pleiotropic effects in cells, in addition to inhibiting proliferation. Currently, if remains unclear if inhibition of lymphocyte proliferation is a relevant mechanism underpinning This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on December 28, 2017 jpet.aspetjournals.org Downloaded from JPET # 74815 5 the immunosuppressive effect of thiopurine drugs. Indeed, overt inhibition of lymphocyte numbers in circulating blood is not required for the therapeutic effects of AZA or 6-MP, but is considered an adverse effect that correlates with the occurrence of opportunistic infections (Connell et al., 1993) .
Since the therapeutic immunosuppression of AZA and 6-MP is evident in the setting of chronic inflammatory diseases, but usually does not predispose to opportunistic infections, we reasoned that these drugs act by selectively affecting activated but not resting immune cells. To test this possibility, we developed an in vitro system of AZAtreated T lymphocytes that models closely the effects of AZA therapy on those cells in vivo. Using a genome-wide expression profiling approach, we evaluated the effects of AZA on the expression of genes in both resting and stimulated T lymphocytes. Our results have identified several immune and inflammation-related genes whose upregulated expression is potently inhibited by thiopurines in activated but not resting T lymphocytes, suggesting potential novel immunosuppressive mechanisms of these drugs.
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METHODS

Reagents:
Unless otherwise stated, reagents were obtained from Sigma-Aldrich Chemical Company (St. Louis, MO)
Cell Culture:
Ju.1 T lymphocytes which stably express the interleukin (IL)-1 receptor were used for these studies (McKean et al., 1995) . Cells were cultured in RPMI supplemented with 5% fetal calf serum and 2mmol/l L-glutamine (Invitrogen, Carlsbad, CA). For experiments, log-growth phase cells were cultured in medium supplemented with varying concentration of AZA, 6-MP or 6-TG. Cells were stimulated with 5µg/ml cross-linked OKT3 (Janssen, Titusville, NJ) plus 0.25 ng/ml recombinant human IL-1α   as previously described (McKean et al., 1995; Kalli et al., 1998) . In some experiments, cells were stimulated using plate-bound OKT3 alone, prepared by incubation of plastic tissue culture plates with a 0.5 µg/ml solution of OKT3 before addition of cells, or in combination with IL-1 or 1:20,000 diluted monoclonal antibody ascites 9.3 anti-CD28 (a gift of Carl June, University of Pennsylvania), which were added to culture medium.
Annexin V and propidium iodide staining:
Cells were collected, washed with cold PBS and re-suspended in tubes containing 
Human Peripheral Blood T Lymphocyte Studies:
After obtaining approval from the Institutional Review Board of the Mayo Foundation, 6 inflammatory bowel disease patients taking AZA and 2 taking 6-MP provided 50 ml blood samples. The mean dose of AZA was 2.1 mg/kg/day for a mean duration of 30 months and the mean dose of 6-MP was 1.15 mg/kg/day for a mean duration of 45 months. Fifty ml of whole blood was divided into two 50ml conical tubes.
Mononuclear cells were extracted from whole blood using Isolymph (GallardSchlesinger, Plainview, NY), according to manufacturer's instructions. Phagocytic cells were removed by L-leucine methyl ester incubation and then cells were filtered through nylon mesh to remove platelet clumps. T cell rosetting was performed using sheep RBCs (Colorado serum, Denver, CO) and ammonium chloride potassium lysis buffer (Cambrex, East Rutherford, NJ). The isolated T lymphocytes were re-suspended in RPMI culture medium supplemented with 10% fetal calf serum, and under these purification procedures have been found to contain less than 5% cells other than T lymphocytes.
6-TGN assay:
Intacellular 6-TGN concentration was measured as described previously ).
This article has not been copyedited and formatted. The final version may differ from this version. Total RNA was isolated from Ju.1 cells and purified using commercial affinity resin column kits (Qiagen, Chatsworth, CA). cDNA was prepared from a total of 10 µg RNA pooled from 3 independent experiments to minimize the effect of random variation on the expression profiles. The purified cDNA was used as a template for in vitro transcription reaction for the synthesis of biotinylated cRNA using RNA transcript labeling reagent (Affymetrix, Santa Clara, CA). Labeled cRNAs were then fragmented and hybridized onto the U133A array. Appropriate amounts of fragmented cRNA and control oligonucleotide B2 were added along with control cRNA (BioB, BioC, BioD), 
Gene Chip Data analysis:
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Real-time reverse transcription (RT)-PCR:
cDNA was prepared using Superscript II (Invitrogen). Sequence specific RT-PCR primers were designed using Affymetrix and Primer 3 algorithms (sequences available on request). Real-time PCR reactions were carried out using SYBR Green master mix on a 7700 Sequence Detector instrument (Applied Biosystems, Foster City, CA). Relative mRNA expression between samples was quantified using the ∆Ct method where β-actin mRNA was utilized as an internal control, as previously described .
This article has not been copyedited and formatted. The final version may differ from this version. hours later, cells were collected, washed and RNA was extracted. This experiment was conducted on 3 independent occasions, and equal amounts of RNA were pooled from the 3 experiments for each condition. The pooled RNA was then processed for gene chip hybridization. was significantly (> 2-fold) affected by AZA in Ju.1 cells that were stimulated with OKT3 plus IL-1. We identified 11 genes that were significantly downregulated by AZA treatment. Most of these genes were involved in immune functions. In 8 of these 11 genes downregulated by AZA, stimulation had induced an upregulation of expression. Fifteen genes were upregulated by AZA in stimulated Ju.1 cells, and most of these were involved in metabolism. The effect of stimulation on these genes was varied.
Real time RT-PCR analysis of candidate gene expression
Gene chip studies identified many genes whose expression was affected by AZA, including some with prominent immune and inflammatory functions. From the lists of genes in tables 1 and 2, we chose for further study by real-time RT-PCR, 2 genes whose upregulated expression was dampened by AZA in stimulated Ju.1 cells, TNF ligand superfamily member 10, also known as TRAIL, and TNF receptor superfamily member 7 (TNFRSF7). We also further studied α4-integrin, a gene whose expression was downregulated by AZA in unstimulated Ju.1 cells. Expression of TRAIL mRNA after Ju.1 cell stimulation increased by 32.9 fold compared to unstimulated cells ( Figure 3A ).
In the presence of 10 µmol/l AZA, the expression of TRAIL was blunted to an increase of 10.7 fold by stimulation. A similar phenomenon was noted in TNFRSF7 expression whereby a 27.7 fold increase was noted after stimulation, which was blunted in the 
Effect of AZA on TRAIL protein expression
For further studies, we focused on TRAIL, since this cytokine shares many similarities with the pro-inflammatory cytokine TNF-α, and plays important roles in immune and inflammatory functions (Smyth et al., 2003) . We used a specific ELISA to quantify the effect of AZA on TRAIL protein production in Ju.1 cells. Stimulation with OKT3 plus IL-1 resulted in marked upregulation of TRAIL expression, which could be blocked by AZA ( Figure 4A ). AZA alone did not affect TRAIL expression, but produced a dose-dependent inhibition of stimulated TRAIL expression in Ju.1 cells ( Figure 4B ).
The inhibitory effect of AZA on TRAIL expression was progressive with increasing durations of pre-treatment with AZA prior to stimulation, up to 48 hours ( Figure 4C ). This is consistent with the time-dependent accumulation of 6-TGN in AZA-treated cells.
To extend the observations in Ju.1 cells, we also evaluated the effect of AZA on TRAIL expression in primary T lymphocytes. TRAIL was not detected in unstimulated primary Through a complex metabolic pathway (Aarbakke et al., 1997) , thiopurine drugs lead to the intracellular accumulation of 6-TGNs, which interfere with the synthesis of DNA, affect the expression of certain genes, and inhibit cell proliferation. For these reasons, 6-TGNs are likely to be the active metabolites of thiopurines that mediate their therapeutic effects. In some studies, circulating 6-TGN levels have been proposed for therapeutic drug monitoring during thiopurine treatment of inflammatory bowel disease (Cuffari et al., 1996b; Dubinsky et al., 2000; Cuffari et al., 2001; Dubinsky, 2003) . This is based on the This article has not been copyedited and formatted. The final version may differ from this version. observation that 6-TGN concentration in erythrocytes correlates with the dose of AZA or 6-MP, and in some series 6-TGN correlates with clinical response to these drugs. However, the clinical utility of measuring 6-TGN levels in inflammatory bowel disease patients has been challenged by studies that found no correlation with clinical response when thiopurine dose had been adjusted for thiopurine methyltransferase activity ).
Nevertheless, the importance of 6-TGN is further supported by the apparent clinical benefit of 6-TG therapy in inflammatory bowel disease patients (Dubinsky et al., 2003a ).
Unfortunately, 6-TG appears to cause significant hepatotoxicity, seriously limiting it's clinical utility (Dubinsky et al., 2003b) .
While most studies have measured the concentration of 6-TGN in erythrocytes since these cells are easily obtained, we wished to measure 6-TGN concentration in relevant target cells. We therefore purified lymphocytes from peripheral blood of inflammatory bowel disease patients receiving standard doses of AZA or 6-MP and measured 6-TGN in those cells and in erythrocytes. We found a much higher concentration in lymphocytes, which probably reflects incorporation of 6-TGN into cellular DNA. Our results of 6-TGN accumulation in leukocytes are consistent with prior reports (Cuffari et al., 1996a) .
We utilized a genome-wide expression-profiling approach to identify genes in a T lymphocyte model, whose up-regulated expression was inhibited by AZA at concentrations that are pharmacologically relevant and result in 6-TGN levels that are seen in vivo. Using this approach, we identified 8 genes whose upregulated expression was inhibited more than 2-fold by AZA. Among these AZA-regulated genes were 2 that are known to possess important immune and inflammation-related functions, TRAIL and TNFRSF7. TRAIL, also known as Apo-2 ligand is a member of the TNF superfamily of cytokines. TRAIL is acting as "decoys" to buffer the effects of TRAIL (Sheridan et al., 1997) . TRAIL, acting through DR4, initiates caspase activation that results in apoptosis, primarily of transformed cells (Smyth et al., 2003) . Considering the established potential for AZA and 6-MP to induce non-Hodgkins lymphomas, it is intriguing to speculate that inhibition of TRAIL expression, an important inducer of apoptosis in transformed lymphocytes, might represent a molecular mechanism for lymphomagenesis in thiopurine-treated patients.
The actions of TRAIL on non-transformed cells include induction of nuclear factor κB, which tends to counterbalance caspase activation, in a manner similar to that observed with TNF. Recent reports have highlighted the function of plasma membrane-associated TRAIL as a receptor for DR4. In this model, TRAIL transmits a signal into the cells on which it is expressed, for example lymphocytes, when ligated by DR4 that is expressed on other cells (Chou et al., 2001) . In lymphocytes, this results in proliferation and interferon-γ secretion, markers of activation. Thiopurine-mediated interference in such a mechanism could dampen over-active immune responses, such as occur in inflammatory bowel disease.
This article has not been copyedited and formatted. The final version may differ from this version. We also identified TNFRSF7 (CD27) as a gene upregulated by T lymphocyte activation that is significantly inhibited by AZA. TNFRSF7 is member of the TNF receptor superfamily that is involved in the regulation of T lymphocyte activation, as assessed by nuclear factor κB activation and interferon-γ secretion (Yamamoto et al., 1998) . Recent evidence suggests that T lymphocyte activation after ligation of the T cell receptor can be significantly augmented by signaling from TNFRSF7 when this receptor is activated by its ligand CD70 (Prasad et al., 1997; Hendriks et al., 2000) . Along with the inhibitory effect on TRAIL expression, down-regulation of TNFRSF7 by AZA would decrease the responsiveness of T lymphocytes to activation, an immunomodulating effect consistent with this drugs clinical effects.
The expression profiling studies also identified α4-integrin as an AZA-regulated gene. T lymphocyte stimulation had little effect on the expression levels of α4-inregrin, but AZA resulted in a significant down-regulation of it's expression on quiescent cells. While real time RT-PCR studies did not confirm lower expression of α4-integrin in AZA-treated unstimulated cells, we did observe significantly lower expression of this gene in AZAtreated cells after stimulation. These discrepancies highlight the need to confirm gene chip data with an independent technique. We chose α4-inregrin for further study because of compelling recent evidence that implicates this adhesion molecule in the pathogenesis of 2 important immunological diseases, Crohn's disease and multiple sclerosis (Ghosh et al., 2003; Miller et al., 2003) . activated lymphocytes and monocytes from the vasculature into sites of inflammation (Berlin et al., 1995) . Downregulated expression of α4-intergin by AZA might therefore act to inhibit the emigration of T lymphocytes, or monocytes, from blood vessels at sites of inflammation. Such an effect on leukocyte recruitment would serve to decrease injury and inflammation, potentially relevant mechanisms.
A number of recent reports have highlighted the ability of thiopurines to induce apoptosis of activated T lymphocytes. Such an effect could rationally result not only in the anti-neoplastic effects of AZA and 6-MP, but also in immunosuppression since it might reduce the numbers of activated cells causing disease. One report showed that 6-MP could block cell cycle progression of T lymphocytes, and could induce apoptosis, but only if the cells were actively proliferating (Quemeneur et al., 2003) . In another recent publication, AZA or 6-MP, acting through their 6-thio-GTP metabolites, were found to block Rac1 (Tiede et al., 2003) . In activated lymphocytes, this resulted in apoptosis, but only after prolonged incubation over several days. Our results point towards an alternative anti-inflammatory or immunosuppressive effect of thiopurine drugs, in which the stimulus-induced expression of specific genes by T lymphocytes is greatly inhibited.
AZA-treated Ju.1 cells did not undergo apoptosis significantly more than control cells under the conditions of our experiments. However, our results are not inconsistent with those of Quemeneur (Quemeneur et al., 2003) and Tiede (Tiede et al., 2003) lymphocytes. In the presence of T cell activation, as occurs in immunologically-driven diseases, 6-TGN blocks the expression of TRAIL, TNFRS7 and α4-integrin, effects which functionally decrease inflammation. These findings provide a new framework for understanding thiopurine-mediated immunosuppression, and further studies will establish the specific roles of these gene products in mediating the beneficial effects of AZA and 6-MP in immune diseases.
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